Friday 6 November 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.

Revenue: −90.6%
EPS: −2,166.7%
Free cash flow: −385.5%

Quarter to June 2026, against a year earlier

29.52 0.78 +2.71%

Follow ZYME

Alert me

Market cap: $2.0B
P/E: 0.0×
Fwd P/E: 26.0×
Dividend yield: —
F-score: 7/9
Altman Z: 11.56
Beneish M: n/a
Dividend safety: n/a

Overview

Zymeworks Inc. (ZYME) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Zymeworks Inc. (ZYME) trades at a P/S ratio of 56.8×. Over the past ten years it has ranged from 0.9× (September 2023) to 111× (December 2020); the current reading is higher than 87% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ZYME/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Zymeworks Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ZYME/metrics/ps-ratio">Zymeworks Inc. (ZYME) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	18.7×	28.75%
FY2024	14.6×	54.75%
FY2023	9.4×	689.11%
FY2022	1.2×	(96.24%)
FY2021	31.7×	(48.19%)
FY2020	61.1×	4.49%
FY2019	58.5×	626.37%
FY2018	8.1×	147.42%
FY2017	3.3×	(79.15%)
FY2016	15.6×	0.00%

Period	P/S ratio	Change
Jun 2026	51.4×	123.37%
Mar 2026	23.0×	22.80%
Dec 2025	18.7×	94.71%
Sep 2025	9.6×	25.05%
38 more quarters	Free account

Against its own ten years

Low 0.9× High 111×

Ten-year median 14.6×

Current reading's percentile 87

Company	P/S ratio
COAG Hemab Therapeutics Holdings, Inc. compare	n/m
VERA Vera Therapeutics, Inc. compare	n/m
BHVN Biohaven Ltd. compare	2.1×
AUPH Aurinia Pharmaceuticals Inc compare	6.7×
LKFT Lakefront Biotherapeutics - Sponsored ADR compare	7.9×
VCEL Vericel Corporation compare	8.1×
SEPN Septerna, Inc. compare	21.8×
ZYME Zymeworks Inc.	56.8×
IMNM Immunome, Inc. compare	162×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Zymeworks Inc. (ZYME) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ZYME

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ZYME

Stockrow Weekly